Stocks Health care VTGN
NASDAQ · Health careVistagen Therapeutics, Inc. (VTGN)
Vistagen Therapeutics, Inc. brought in $2.5M of revenue over the twelve months to June 30, 2026, up 287.2% from a year earlier. It posted a net loss of $67.6M. At June 30, 2026 it held $17M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Vistagen Therapeutics, Inc.
- Net worth
- Vistagen Therapeutics, Inc. has a market value (market cap) of $8.2M at the latest share price, and shareholders' equity of $24.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2026 revenue was $1.3M (+161.1% year on year), with a net loss of $69.7M. Over the 12 months to June 30, 2026: revenue $2.5M, net loss $67.6M.
- Cash flow
- In fiscal 2026 operations used $66.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Vistagen Therapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Vistagen Therapeutics, Inc. does
Vistagen Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VTGN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | $1.3M | -$69.7M | -$1.83 | n/a |
| 2025 | $486K | -$51.4M | -$1.67 | n/a |
| 2024 | $1.1M | -$29.4M | -$1.52 | -$25.8M |
| 2023 | -$227K | -$59.2M | -$8.51 | -$50.2M |
| 2022 | $1.1M | -$47.8M | -$7.38 | -$45.5M |
| 2021 | $1.1M | -$17.9M | -$0.49 | -$12.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where VTGN ranks in Health care
Latest SEC filings
What Vistagen Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 25, 2026
- September 24, 2026Other event 8-K
- September 22, 2026Other event 8-K
- September 11, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 505% to $1.5M versus the same quarter last year; diluted EPS -$0.30 versus -$0.47.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026
- August 6, 2026
Insider trades
What the people running Vistagen Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 30, 2026 | Singh ShawnPresident and CEO, Director | Received as pay | 36,818 | $7.1K |
| June 30, 2026 | Tressler Nick B.Chief Financial Officer | Received as pay | 11,712 | $2.2K |
| June 30, 2026 | Adler Reid G.Chief Legal Officer | Received as pay | 36,818 | $7.1K |
| December 31, 2025 | Prince Joshua S.Chief Operating Officer | Received as pay | 4,386 | $2.5K |
Who owns VTGN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bvf Partners L P13G, passive with 9 related filers | 9.97% | February 14, 2025 |
| Commodore Capital LP13G, passive with 3 related filers | 9.9% | August 14, 2026 |
| Chen Yu13G, passive with 4 related filers | 6.7% | August 14, 2026 |
Largest institutional holders
Insiders
4 insiders reported holding 142,675 shares in total, about $26.2K at the last price.
| Holder | Shares |
|---|---|
| Adler Reid G.Chief Legal Officer | 60,868 |
| Singh ShawnPresident and CEO, Director | 54,846 |
| Prince Joshua S.Chief Operating Officer | 15,249 |
| Tressler Nick B.Chief Financial Officer | 11,712 |
Questions about VTGN
What does Vistagen Therapeutics, Inc. do?
Vistagen Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as VTGN. Its shares trade on NASDAQ under the ticker VTGN.
What is Vistagen Therapeutics, Inc.'s net worth?
Vistagen Therapeutics, Inc. has a market value (market cap) of $8.2M at the latest share price, and shareholders' equity of $24.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Vistagen Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $67.6M on revenue of $2.5M.
How much revenue does Vistagen Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Vistagen Therapeutics, Inc. reported revenue of $2.5M. That is 287.2% more than a year earlier.
When did Vistagen Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 25, 2026.
When is Vistagen Therapeutics, Inc.'s next earnings report?
Vistagen Therapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare VTGN with
Follow VTGN
Get an email when Vistagen Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Vistagen Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.